2C Tech intends to validate and develop the potential of Nanoparticle technologies to provide effective and meaningful therapeutic benefits to patients with retinal degenerative conditions. Our immediate focus is on the use of Quantum Dots (QDs) as a therapeutic option for patients with Retinitis Pigmentosa.
We will continuously focus on patient outcomes as our primary measure of organization success; and we will harness the power of cutting edge technologies to preserve or enhance visual function in patients with diseases or conditions that would otherwise result in premature vision loss.
2C Tech, Inc. is committed to providing safe and effective medical devices for the treatment of ophthalmic diseases. We will achieve this goal by:
- Fostering an environment of integrity, innovation, and high quality standards
- Soliciting customer feedback and implementing continuous improvement of our products
- Ensuring compliance with the applicable regulatory requirements
- Maintaining the effectiveness of the Quality Management System (QMS) while in compliance with applicable regulatory requirements.
Age-related Macular Degeneration
Sixteen million Americans suffer from various ocular diseases, such as retinitis pigmentosa, retinal detachment, diabetic retinopathy, and macular degeneration, which ultimately lead to diminished sight and eventually blindness. The number of such people is growing rapidly as the age of the general population increases.